News | Congenital Heart | July 06, 2022

New Understanding of Congenital Heart Disease Progression Opens Door to Improved Treatment Options

Scientists develop a roadmap to future personalized medicine for heart defects that develop before birth 

Scientists develop a roadmap to future personalized medicine for heart defects that develop before birth

Getty Images


July 6, 2022 — A team of investigators from Texas Heart Institute, Texas Children’s Hospital and Baylor College of Medicine uncovered new insights into the mechanisms underlying the progression of congenital heart disease (CHD) ― a spectrum of heart defects that develop before birth and remain the leading cause of childhood death.  

The research published in Nature represents the first reported single-cell genomics evidence of unique differences in heart muscle cells and immune systems of CHD patients. Uncovering these key differences and how these diseases progress provides an opening for researchers to devise new ways to treat CHD. 

While the eventual outcome of heart failure in CHD is well documented, the underlying cause of declining heart function in these patients is still poorly understood. That knowledge gap in understanding has led to roadblocks in developing new therapies capable of extending a patient’s life. 

To address these unanswered questions, Texas Heart Institute and Baylor College of Medicine’s James F. Martin, MD, PhD, collaborated with Iki Adachi, MD, Director of the Mechanical Circulatory Support Program at Texas Children’s and Associate Professor at Baylor College of Medicine, and Diwakar Turaga, MD, PhD, a Texas Children’s Hospital pediatric cardiac critical care specialist and Assistant Professor at Baylor College of Medicine, to profile heart and blood samples from CHD patients. The team studied patients with hypoplastic left heart syndrome (HLHS), Tetralogy of Fallot (TOF) and dilated (DCM) and hypertrophic (HCM) cardiomyopathies undergoing heart surgery.  

Dr. Martin is an internationally recognized physician-scientist who has made numerous fundamental contributions to our understanding of cardiac developmental and disease pathways, as well as tissue regeneration.  

“Using several exciting new technologies such as single-cell RNA sequencing, we were able to interrogate samples from congenital heart disease patients at the single cell level. One of our goals is to improve the natural history of this terrible disease afflicting children,” said Dr. Martin, Director of the Cardiomyocyte Renewal Laboratory at the Texas Heart Institute and Vivian L. Smith Professor in the Department of Integrative Physiology at Baylor College of Medicine. “There is still a lot of work to do as the team, including co-first authors Drs. Matthew C. Hill, Zachary A. Kadow and Hali Long, heads toward that goal.” 

Dr. Turaga is a physician-scientist dedicated to bringing cardiac regenerative medicine therapies to the bedside. 

“This is the first step in developing a comprehensive cell atlas of congenital heart disease,” said Dr. Turaga, physician in the Cardiac Intensive Care Unit at Texas Children’s, as well as an expert in genomics and microscopy. “We are creating a roadmap for therapies targeting individual cell types and unique gene pathways in CHD that include both the heart and the immune system, something that had not been reported before. As the technology matures, this will become the standard of care in treatment of CHD.” 

Dr. Adachi is a congenital heart surgeon at Texas Children’s Hospital who is specialized in reconstructive surgical procedures of CHD lesions including those analyzed in this study. 

“What we achieved with this study is absolutely exciting but represents just the beginning,” said Dr. Adachi, director of the world’s largest pediatric Heart Transplant and Ventricular Assist Device Program. “The collaboration between the extremely sophisticated laboratory at the Texas Heart Institute and the top pediatric heart center at Texas Children’s definitely has the potential to go further.” 

The findings of the study not only provide a new roadmap to develop personalized treatments for CHDs, but also provide the scientific community with a critical resource of rare pediatric heart samples that can be used to make further discoveries and deepen our understanding of CHD.  

For more information: https://www.texasheart.org 

Related Content

News | Heart Failure

August 8, 2022 — A major risk factor for diabetes, insulin resistance occurs when the cells of the body do not respond ...

Home August 08, 2022
Home
News | Heart Failure

August 5, 2022 — For people with coronary heart disease, beta-blockers can improve survival and quality of life, while ...

Home August 05, 2022
Home
News | Heart Failure

July 27, 2022 — The world’s first HIV-positive to HIV-positive heart transplant has been successfully performed at ...

Home July 27, 2022
Home
News | Heart Failure

July 27, 2022 — Researchers from RCSI University of Medicine and Health Sciences have developed a new lab-based model of ...

Home July 27, 2022
Home
News | Heart Failure

July 20, 2022 — Sequana Medical NV, a pioneer in the treatment of drug-resistant fluid overload in liver disease and ...

Home July 20, 2022
Home
News | Heart Failure

July 15, 2022 — The American Heart Association, the leading voluntary organization devoted to longer, healthier lives ...

Home July 15, 2022
Home
News | Heart Failure

July 13, 2022 — Ancora Heart, Inc., a company developing a novel device-based therapy to address heart failure, today ...

Home July 13, 2022
Home
News | Heart Failure

July 12, 2022 — Pesticides and heavy metals in soil may have detrimental effects on the cardiovascular system, according ...

Home July 12, 2022
Home
News | Heart Failure

July 7, 2022 — Tenaya Therapeutics, Inc., a biotechnology company with a mission to discover, develop and deliver ...

Home July 07, 2022
Home
News | Heart Failure

June 29, 2022 — A spiral wave of electrical activity in the heart can cause catastrophic consequences. One spiral wave ...

Home June 29, 2022
Home
Subscribe Now